NEW YORK, NY – Researchers at Weill Cornell Medicine have announced a new precision medicine approach for treating ovarian cancer. A combination of two experimental drugs, including a medication known as rigosertib, has shown high efficacy in inhibiting tumor growth and preventing drug resistance in preclinical trials.
The study, published recently, details how the dual-drug therapy targets specific pathways in cancer cells, offering a highly focused attack on ovarian tumors. This method addresses one of the most significant challenges in ovarian cancer treatment: the tendency for tumors to develop resistance to standard chemotherapy over time.
In the preclinical studies, the combination therapy not only effectively suppressed the growth of cancer cells but also demonstrated the ability to block the mechanisms that lead to drug resistance. This suggests the treatment could remain effective for longer periods compared to existing options.
While the results are from a preclinical stage and have not yet been tested in large-scale human trials, the discovery offers significant hope for developing more effective and durable treatments for ovarian cancer. The researchers are optimistic that these promising findings will pave the way for future clinical trials in patients.
